Summary
Nonalcoholic fatty liver (NAFL) or nonalcoholic fatty liver disease (NAFLD) as it is often called, is increasingly recognized as a common and potentially severe condition often associated with obesity, type 2 diabetes, and hyperlipidemia. The spectrum of disorders which fall under the term ‘NAFL’ include simple steatosis, steatosis with mild inflammation, and steatosis with inflammation and varying degrees of fibrosis. Most investigators reserve the term ‘NASH’ (nonalcoholic steatohepatitis) for those patients who have some degree of fibrosis, usually associated with increased numbers of ballooned hepatocytes. The prognosis varies, but it is now evident that a substantial portion of patients, especially those with NASH, will progress to cirrhosis with all of the attendant complications, and some may ultimately develop hepatocellular cancer. Well-developed cirrhosis may lose its fat content and appear as ‘cryptogenic cirrhosis’. Lipid peroxidation of the excess oil in the liver appears to be the major pathogenic mechanism. The process appears to alter mitochondrial form and function. Initial treatment usually involves exercise and dietary modifications. Patients who fail this approach or who have more advanced conditions initially may be candidates for more aggressive measures, including drug therapy. Many agents have been reported in small series but all remain investigational.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Key words
References
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413–1419
Cotrim HP, De Freitas LA, Freitas C, Braga L, Sousa R, Carvalho F, Parana R, Santos-Jesus R, Andrade NASH in workers exposed to chemicals with or without associated metabolic conditions. Liver Int 2004
Morgan W (1877) The Liver and its Diseases, Both Functional and Organic. Their History, Anatomy, Chemistry, Pathology, Physiology, and Treatment. Homoeopathic, London, University of Virginia Historical Collection, p 144
Tumen HJ, Cohn EM (1946) Cirrhosis. In: Bockus HL (ed) Gastroenterology, vol. III. Saunders, Philadelphia, pp 385–392
Zelman S (1958) The liver in obesity. Arch Intern Med 90: 141–156
Faloon WW (1988) Hepatobiliary effects of obesity and weight-reducing surgery. Semin Liver Dis 8: 229–236
Ludwig J, Viggiano TR, McGill DB, Ott BJ (1980) Nonalcoholic steatohepatitis. Mayo Clin Proc 55: 434–438
Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123: 1705–1725
Cairns SR, Peters TJ (1983) Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin Sci 65: 645–652
James OFW (2002) NASH/NAFLD Management. AASLD Single Topic Conference on NASH Syllabus, Atlanta, Georgia
Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132: 112–117
Clark JM, Brancati FL, Diehl AM (2001) Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the US population (abstract). Gastroenterology 120: 65
Nomura H, Kashiwagi S, Hayashai J, Kujiyama W, Tani S, Goto M (1988) Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 27: 142–149
Siegelman ES, Rosen MA (2001) Imaging of steatosis. Semin Liver Dis 21: 71–80
Van der Kooy K, Seidell JC (1993) Techniques for the measurements of visceral fat: a practical guide. Int J Obes 17: 187–196
Saadeh S, Younossi ZM, Remer EM, Gramlish T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745–750
Celle G, Savarino V, Picciotto A, Magnolia MR, Scalabrini P, Dodero M (1988) Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. Dig Dis Sci 33: 467–471
Quinn SF, Gosink BB (1985) Characteristic sonographic signs of hepatic fatty infiltration. AJR Am J Roentgenol 145: 753–755
Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, Horii SC (1998) Diagnostic criteria for fatty infiltration of the liver on contrast enhanced helical CT. AJR Am J Roentgenol 171: 659–664
Levenson H, Greensite F, Hoefs J, Friloux L, Applegate G, Silva E, Kanel G, Buxton R (1991) Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. AJR Am J Roentgenol 156: 307–312
Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM (1999) Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282: 1659–1664
Hilden M, Juhl E, Thomsen AC, Christoffersen P (1973) Fatty liver persisting for up to 33 years. Acta Med Scand 194: 485–489
Teli MR, James OFW, Burt AD, Bennett MK, Day CP (1995) The natural history of nonalcoholic fatty liver: a followup study. Hepatology 22: 1714–1719
Harrison SA, Torgerson S, Hayashi PH (2003) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98: 2042–2047
Powell EE, Cooksley WG, Hanson R, Searll J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 11: 74–80
Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664–669
Poonawala A, Nair SP, Thuluvath PJ (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689–692
Mendiola AE, Gish RG (2001) Risk factors for NASH in patients with cryptogenic cirrhosis (abstract). Gastroenterology 120: 545
Contos MJ, Cales W, Sterling RK, Lukeric VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ (2001) Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7: 363–373
Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U (2002) Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 33: 1098–1104
Basaranoglu M, Ozbay G, Caldwell SH, Sonsuz A (2003) Refinement of a clinicopathological typing system for NAFLD (abstract). Hepatology 34: 505A
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 94: 2467–2474
Mendler MH, Yashar B, Govindarajan S, Kanel G (2002) A novel semi-quantitative histological scoring system for non-alcoholic fatty liver disease: evaluation and clinical correlations (abstract). Hepatology 36: 407
Navarro VJ, St Louis T, Bell BZ, Sofair AN (2003) Chronic liver disease in the primary care practices of Waterbury, Connecticut. Hepatology 38: 1062–1063
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923
Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37: 1202–1219
Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G (2000) Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sciences 45: 1929–1934
Rashid M, Roberts EA (2000) Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 30: 48–53
Struben VMD, Hespenheide EE, Caldwell SH (2000) Familial patterns of nonalcoholic steatohepatitis and cryptogenic cirrhosis. Am J Med 108: 9–13
Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA (2001) Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am J Gastroenterol 96: 2957–2961
Cortez-Pinto H, Camilo ME, Baptista A, de Oliveira AG, De Moura MC (1999) Nonalcoholic fatty liver: another feature of the metabolic syndrome. Clin Nutr 18: 353–358
Knobler H, Schatter A, Zhornicki T, Malnick SD, Keter D, Sokolovsaya N, Lurie Y, Bass DD (19999) Fatty liver—an additional and treatable feature of the insulin resistance syndrome. QJM 92: 73–79
Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y (1995) Association between hepatic steatosis, insulin resistance, and hyperinsulinemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 9: 101–105
Lobo RA, Carmino E (2000) The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132: 989–993
Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP (1997) Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III (1988 to 1994). Obesity Res 5: 542–548
NHLBI Obesity Task Force (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obesity Res 6(Suppl 2): 51S–209S
Lee JH, Rhee PL, Lee JK, Lee KT, Kim JJ, Koh KC, Paik SW, Rhee JC, Choi KW (1998) Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Korean J Intern Med 13: 12–14
Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE (1999) Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 84: 137–144
Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M (2002) Nonalcoholic steatohepatitis, insulin resistance and metabolic syndrome: further evidence for an etiologic association. Hepatology 35: 367–372
Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35: 373–379
Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ (1994) Waist circumference and abdominal sagittal diameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73: 460–468
Ong JP, Hazem E, Younoszai A, Goodman Z, Grant G, Christensen A, Chandhoke V, Cooper J, Bopari N, Younossi ZM (2002) Predictors of non-alcoholic steatohepatitis and fibrosis in non-alcoholic fatty liver disease (abstract). Hepatology 36: 407
Kuczmarski RJ (1989) Need for body composition information in elderly subjects. Am J Clin Nutr 50: 1150–1157
Andersen T, Gluud C (1984) Liver morphology in morbid obesity: a literature study. Int J Obes 8: 97–106
Andersen T, Christoffersen P, Gluud C (1984) The liver in consecutive patients with morbid obesity: a clinical, morphological and biochemical study. Int J Obes 8: 107–115
Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T (2000) Liver fibrosis in overweight patients. Gastroenterology 118: 1117–1123
Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, Larranaga E, Moreno-Otero R (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33: 716–724
Braillon A, Capron JP, Herve MA, Degott C, Quenum C (1985) Liver in obesity. Gut 26: 133–139
Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N (1999) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107: 450–455
Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G (2000) Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 45: 1929–1934
Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD (1999) Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 31: 430–434
Sozo A, Arrese M, Glasinovic JC (2001) Evidence of intestinal bacterial overgrowth in patients with NASH (abstract). Gastroenterology 120: 118
Gamez J, Ferreiro BS, Accarino ML, Guarner L, Tadesse S, Marti RA, Andreu AL, Raguer N, Cervera C, Hirano M (2002) Phenotypic variation in a Spanish family with MNGIE. Neurology 59: 455–457
Powell EE, Searle J, Mortimer R (1989) Steatohepatitis associated with limb lipodystrophy. Gastroenterology 97: 1022–1024
Feliciani C, Amerio P (1999) Madelung’s disease: inherited from an ancient Mediterranean population? N Engl J Med 340: 1481
Wasserman JM, Thung SN, Berman R, Bodenheimer HC, Sigal SH (2001) Hepatic Weber-Christian disease. Semin Liver Dis 21: 115–118
Dahl MG, Gregory MM, Scheuer PJ (1971) Liver damage due to methotrexate in patients with psoriasis. BMJ 1: 625–630
Pirovino M, Muller O, Zysset T, Honegger U (1988) Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatology 8: 591–598
Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC (1995) Tamoxifen-associated steatohepatitis—report of three cases. J Hepatol 23: 95–97
Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA (1999) Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 19: 263–264
Chitturi S, Farrell GC (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21: 27–41
Caldwell SH, Hespenheide EE (2002) Subacute liver failure in obese females. Am J Gastroenterol 97: 2058–2062
Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664–669
Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35: 1485–1493
Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, Larranaga E, Moreno-Otero R (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33: 716–724
Mathieson UL, Franzen LE, Fryden A, Foberg U, Bodemar G (1999) The clinical significance of slightly to moderately elevated liver transaminase values in asymptomatic patients. Scand J Gastroenterol 34: 85–91
Patt CH, Yoo HY, Dibadj K, Flynn J, Thuluvath PJ (2003) Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive healthscreening program. Digestive Diseases & Sciences 48(4): 797–801
Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD (2000) An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 95: 3206–3210
Hay JE, Czaja AJ, Rakela J, Ludwig J (1989) The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 9: 193–197
Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M (1999) Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94: 3010–3014
Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96: 519–525
Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ (2003) Clinical and histologic spectrum of NAFLD associated with normal ALT values. Hepatology 37: 1286–1292
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137: 1–10
Shan Y, Bigelow C, Bonkovsky HL (2002) Prevalence of liver disease in the US population and association with iron homeostasis: analysis of data from NHANES III (abstract). Hepatology 36: 408
Bonkovsky H, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht R, Banner B (1999) Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31: 421–429
George D, Goldwurm S, MacDonald G, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW (1998) Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114: 311–318
Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356–1362
Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O’Neill R, McCullough AJ (1999) Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30: 847–850
Tumiel M, Whitcomb BJ, Krawitt EL (1994) Circulating antinuclear antibodies in patients with nonalcoholic steatohepatitis (abstract). Hepatology 20: 409
Tajiri K, Takenawa H, Yamaoka K (1997) Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastrroenterol 25: 538–540
Nagore N, Scheuer PJ (1988) Does a linear pattern of sinusoidal IgA deposition distinguish between alcoholic and diabetic liver disease? Liver 8: 281–286
Caldwell SH, Hespenheide EE (2001) Obesity and cryptogenic cirrhosis. In: Leuschner U, James O, Dancygier H (eds) Steatohepatitis (ASH and NASH). Falk Symposium 121. Kluwer Academic, Norwell, MA, p 151
Kanjii K, Jakate S, Keshavarzian A, Jensen DM, Cotler SJ (2003) Prevalence and clinical features of associated autoantibodies in NASH. Hepatology 34: 506A
Rosado-Carrion B, Lindor K, Talwalker J, Miles J, Rizza R, Gorman B, Charlton M (2003) Continuous glucose monitoring and metabolic evidence of subclinical glucose intolerance in NAFLD: looking beyond the tip of the insulin resistance iceberg. Hepatology 34: 508A
Adams LA, Keach J, Lindor KD, Angulo P (2003) Lipid profiles in NAFLD. Hepatology 34: 512A
Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356–1362
Nanji AA, French SW, Freeman JB (1986) Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 36: 266–269
Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD (2000) An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 95: 3206–3210
Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, Larranaga E, Moreno-Otero R (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33: 716–724
Struben VMD, Hespenheide EE, Caldwell SH (2000) Familial patterns of nonalcoholic steatohepatitis and cryptogenic cirrhosis. Am J Med 108: 9–13
Dixon JB, Bathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91–100
Harrison SA, Hayashi P (2002) Clinical factors associated with fibrosis in 102 patients with non-alcoholic steatohepatitis (abstract). Hepatology 36: 412
Costanzo M, Miele L, Di Rocco P, Forgione A, Alfei B, Pompili M, Rapacini GL, Grieco A, Gasbarrini G (2002) Serum markers of fibrogenesis and fibrosis in nonalcoholic steatohepatitis (abstract). Hepatology 36: 412
Iijima H, Moriyasu F, Tsuchiya K, Sasaki S, Suzuki S (2003) Diagnosis of NASH using Kupffer imaging of contrast enhanced ultrasound. Hepatology 34: 514A
Ratziu V, Le Calvez S, Imber-Bismut F, Messous D, Charlotte F, Bonyhay L, Munteanu M, Poynard T (2003) Diagnostic value of biochemical markers (Fibrotest) for the prediction of liver fibrosis in patients with NAFLD. Hepatology 34: 510A
Merriman RB, Ferrell LD, Patti MG, Ostroff JW, Bagetelos K, Aouizerat BE, Bass NB (2003) Histologic correlation of paired right and left lobe biopsies in morbidly obese individuals with suspected NAFLD. Hepatology 34: 232A
Ewe K (1981) Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 26: 388–393
Piccinino F, Sagnelli E, Pasquale G, Giusti G (1986) Complication following percutaneous liver biopsy. A multicenter retrospective study on 68 276 biopsies. J Hepatol 2: 165–173
Caldwell SH (2001) Controlling pain in liver biopsy. Am J Gastroenterol 96: 1327–1329
Janes CH, Lindor KD (1993) Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 118: 96–98
Byron D, Minuk GY (1996) Profile of an urban hospital-based practice. Hepatology 24: 813–815
Mathieson UL, Franzen LE, Fryden A, Foberg U, Bodemar G (1999) The clinical significance of slightly to moderately elevated liver transaminase values in asymptomatic patients. Scand J Gastroenterol 34: 85–91
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413–1419
Saadeh S, Younossi ZM, Remer EM, Gramlish T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745–750
Hilden M, Juhl E, Thomsen AC, Christoffersen P (1973) Fatty liver persisting for up to 33 years. Acta Med Scand 194: 485–489
Teli MR, James OFW, Burt AD, Bennett MK, Day CP (1995) The natural history of nonalcoholic fatty liver: a followup study. Hepatology 22: 1714–1719
Lee RG (1989) Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20: 594–598
Powell EE, Cooksley WG, Hanson R, Searll J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 11: 74–80
Bacon BR, Farahvish MJ, Janney CG, Neuschwander-Tetri BA (1994) Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107: 1103–1109
Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I et al (2000) Liver fibrosis in overweight patients. Gastroenterology 118: 1117–1123
Harrison SA, Torgerson S, Hayashi PH (2003) The natural history of NAFLD: a clinical histopathological study. Am J Gastroenterol 98: 2042–2047
Gaede P, Vedel P, Larsen N, Jenesn GVH, Parving H-H, Pendersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393
Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA (2003) Is obesity a risk factor for cirrhosis-related death or hospitalization? A population based cohort study. Gastroenterology 125: 1053–1059
Sasaki A, Horiuchi N, Hasegawa K, Uehara M (1989) Mortality and causes of death in type 2 diabetic patients. Diabetes Res Clin Pract 7: 33–40
Caldwell SH, Han K, Hess CE (1997) Thrombocytopenia and unrecognized cirrhosis. Ann Intern Med 127: 572–573
Sozo A, Arrese M, Glasinovic JC (2001) Evidence of intestinal bacterial overgrowth in patients with NASH. Gastroenterology 120: A–118
Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD (1999) Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 31: 430–434
Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183–1192
Johns DR (1995) Mitochondrial DNA and disease. N Engl J Med 333: 638–644
Al-Osaimi A, Berg CL, Caldwell SH (2002) Intermittent disconjugate gaze: a novel finding in NASH and cryptogenic cirrhosis (abstract). Hepatology 36: 408A
Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS (2003) Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98: 2064–2071
Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U (2002) Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 33: 1098–1104
Powell EE, Cooksley WG, Hanson R, Searll J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 11: 74–80
Nosadini R, Avogaro A, Mollo F, Marescotti C, Tiengo A, Duner E, Merkel C, Gatta A, Zuin R, de Kreutzenberg S et al (1984) Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. J Clin Endocrinol Metab 58: 1125–1132
Contos MJ, Cales W, Sterling RK, Lukeric VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ (2001) Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7: 363–373
Struben VMD, Hespenheide EE, Caldwell SH (2000) Familial patterns of nonalcoholic steatohepatitis (NASH) and cryptogenic cirrhosis. Am J Med 108: 9–13
Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA (2001) Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. American Journal of Gastroenterology 96(10): 2957–2961
Nagore N, Scheuer PJ (1988) Does a linear pattern of sinusoidal IgA deposition distinguish between alcoholic and diabetic liver disease. Liver 8: 281–286
Poonawala A, Nair SP, Thuluvath PJ (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689–692
Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparis N (2001) Cryptogenic cirrhosis and post-transplantation non-alcoholic fatty liver disease. Liver Transplantation 7: 797–801
Nair S, Mason A, Eason J, Loss G, Perillo RP (2002) Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36: 150–155
Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35: 1485–1493
Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G (1995) Hepatic and portal vein thrombosis in cirrhosis: possible role in the development of parenchymal extinction and portal hypertension. Hepatology 21(5): 1238–1247
El-Serag H, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the US: an update. Ann Intern Med 139: 817–823
Ong JP, Younossi ZM (2002) Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 123: 375–378
Murphy TK, Calle EE, Rodriquez C, Khan HS, Thun MJ (2000) Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152: 847–854
Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM (2001) Hepatocyte hyperplasia in non-cirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 61: 5016–5023
El-Sarag HB, Richardson PA, Everhart JE (2001) The role of diabetes in hepatocellular carcinoma: a case control study among United States veterans. Am J Gastroenterol 96: 2462–2467
Cotrim HP, Parana R, Braga E, Lyra L (2000) Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 95: 3018–3019
Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y (2001) Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51: 127–131
Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, de Paolis P, Capussotti L, Salizzoni M, Rizzetto M (2002) Expanding the natural history of nonalcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134–140
Marrero JA, Fontana RJ, Su GL, Conjeevarum HS, Emick DM, Lok AS (2002) NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the US. Hepatology 36: 1349–1354
Day CP, James OFW (1998) Steatohepatitis: A tale of two hits. Gastroenterology 114: 842–845
DiMauro S, Schon EA (2003) Mitochondrial respiratory-chain diseases. N Engl J Med 348: 2656–2668
Carrozzo R, Hirano M, Fromenty B, Casali C, Santorelli FM, Bonilla E, DiMauro S, Schon EA, Miranda AF (1998) Multiple mtDNA deletions features in autosomal dominant and recessive diseases suggest distinct pathogeneses. Neurology 50: 99–106
Hoek JB, Cahill A, Pastorino JG (2002) Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 122: 2049–2063
Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281: 1309–1312
Caldwell SH, Chang C (2004) Mitochondria in NAFL. Clin Liver Dis Ed. AJ Sanyal, in press
Bereiter-Hahn J, Voth M (1994) Dynamics of mitochondria in living cells: shape changes, dislocations, fusion and fission of mitochondria. Microsc Res Tech 27: 198–219
Hepatocyte Ultrastructure Text—University of Virginia library
Kuroiwa T, Ohta T, Kuroiwa H, Shigeyuki K (1994) Molecular and cellular mechanisms of mitochondrial nuclear division and mitochondriokinesis. Microsc Res Tech 27: 220–232
Lea PJ, Temkin RJ, Freeman KB, Mitchell GA, Robinson BH (1994) Variations in mitochondrial ultrastructure and dynamics observed by high resolution scanning electron microscopy (HRSEM). Microsc Res Tech 27: 269–277
Lehmann TG, Wheeler MD, Schwabe RF, Connor HD, Schoonhoven R, Bunzendahl H, Samulski RJ, Thurman RG (2000) Gene delivery of Cu/Zn-superoxide dismutase improves graft function after transplantation of fatty livers in the rat. Hepatology 32: 1255–1264
Dianzani MU (1954) Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. Biochim Biophys Acta 14: 514–532
Dianzani MU (1957) The content of adenosine polyphosphates in fatty livers. Biochem J 65: 116–124
Sternlieb I (1968) Mitochondrial and fatty changes in hepatocytes of patients with Wilson’s disease. Gastroenterology 55: 354–362
Chedid A, Mendenhall CL, Tosch T, Chen T, Rabin L, Garcia-Pont P, Goldberg SJ, Kiernan T, Seeff LB, Sorrell M et al (1986) Significance of megamitochondria in alcoholic liver disease. Gastroenterology 90: 1858–1864
Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD Jr. (1999) Mitochondrial abnormalities in NASH. J Hepatol 31: 430–434
Sanyal AJ, Campbell-Sargent C, Mirshani F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183–1192
Sternlieb I, Berger JE (1969) Optical diffraction studies of crystalline structures in electron micrographs. J Cell Biol 43: 448–455
Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96: 519–525
Williams WP, Selstam E, Brain T (1998) X-ray diffraction studies of the structural organization of prolamellar bodies isolated from Zea mays. FEBS Lett 422: 252–254
Deng Y, Kohlwein SD, Manella CA (2002) Fasting induces cyanide-resistant respiration and oxidative stress in the amoeba Chaos carolinensis: implications for the cubic structural transition in mitochondrial membranes. Protoplasm 219: 160–167
Spycher MA, Ruttner JR (1968) Kristalloide Einschlusse in menschlichen Lebermitochondrien. Virchows Arch B Cell Pathol 1: 211–221
Wolf SG, Frenkiel D, Arad T, Finkel SE, Kolter R, Minsky A (1999) DNA protection by stress-induced biocrystallization. Nature 400: 83–85
Le TH, Caldwell SH, Redick JA, Sheppard BL, Davis CA, Arseneau KO, Iezzoni JC, Hespenheide EE, Peterson T (2004) The lobular distribution of megamitochondria with crystalline inclusions in type 3–4 NAFL
Dianzani MU, Scuro S (1956) The effects of some inhibitors of oxidative phosphorylation on the morphology and enzymatic activities of mitochondria. Biochem J 62: 205–215
Vendemiale G, Grattagliano I, Caraceni P, Caraccio G, Domenicali M, Dall’Agata M, Trevisani F, Guerrieri F, Bernardi M, Altomare E (2001) Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology 33: 808–815
Junnila M, Rahko T, Sukura A, Lindberg LA (2000) Reduction of carbon tetrachloride induced hepatotoxic effects by oral administration of betaine in male Han-Wistar rats: a morphometric histologic study. Vet Med 37: 231–238
Lehmann TG, Wheeler MD, Schwabe RF, Connor HD, Schoonhoven R, Bunzendahl H, Brenner DA, Jude Samulski R, Zhong Z, Thurman RG (2000) Gene delivery of Cu/Znsuperoxide dismutase improves graft function after transplantation of fatty liver in the rat. Hepatology 32: 1255–1264
Trevasani F, Colantoni A, Caraceni P, Van Thiel DH (1996) The use of donor fatty livers for liver transplantation: a challenge or a quagmire. J Hepatol 22: 114–121
Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA (2003) Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38(4): 999–1007
Cortez-Pinto H, Chatham J, Chako VP, Arnold C, Rasid A, Diehl AM (1999) Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282: 1659–1664
Chavin KD, Yang SQ, Lin HZ, Chatham J, Chakko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM (1999) Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 274: 5692–5700
Diehl AM, Hoek JB (1999) Mitochondrial uncoupling: role of uncoupling protein anion carriers and relationship to thermogenesis and weight control, ‘the benefits of losing control’. J Bioenerg Biomembr 31: 493–506
Baffy G, Zhang CY, Glickman JN, Lowell BB (2002) Obesity-related fatty liver is unchanged in mice deficient for mitochondrial UCP-2. Hepatology 35: 753–761
Pessayre D, Mansouri A, Fromenty B (2002) Nonalcoholic steatosis and steatohepatitis V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 282: G193–G199
Caldwell S, Chang C, Redick J, Davis C, Krugner-Higby L, Al-Osaimi A (2004) The ballooned hepatocyte in NAFL: degenerative or adaptive? Submitted to EASL
Ikura Y, Ohsasa M, Ogawa Y, Kaneda K, Hai E, Kayo S, Yoshima N, Shirai N, Sugama Y, Fujino H, Itabe H, Ueda M (2003) Localization of oxidized phosphatidylcholine in steatotic livers: its relation to oxidative injury in fatty liver disorders. Hepatology 34: 507A
Fournier E, Peresson R, Guy G, Hermier D (1997) Relationship between storage and secretion of hepatic lipids in two breeds of geese with different susceptibility to liver steatosis. Poultry Sci 76: 599–607
Krugner-Higby L, Attie A, Schueler K, Thuren T, Shelness G, Wendland A. Hyperlipidemia in California mice (Peromyscus californicus) due to increased hepatic secretion of VLDL
Silva JE (2003) The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 139: 205–213
Dulloo AG (2002) A sympathetic defense against obesity. Science 297: 780–781
Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BB (2002) betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297: 843–845
Li Z, Oben JA, Yang S, Lin H, Diehl AM (2003) Norepinephrin mediates effects of leptin deficiency on hepatic innate immune system in a mouse model of NASH. Hepatology 34: 192A
Struben VMD, Hespenheide EE, Caldwell SH (2000) Familial patterns of nonalcoholic steatohepatitis (NASH) and cryptogenic cirrhosis. Am J Med 108: 9–13
Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA (2001) Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am J Gastroenterol 96: 2957–2961
Caldwell SH, Harris DM, Patrie J, Hespenheide EE (2002) Are NASH and cryptogenic cirrhosis under diagnosed in African Americans? Am J Gastroenterol 97: 1496–1500
Schapira AHV (1997) Mitochondrial disorders: an overview. J Bioenerg Biomembr 29: 105–107
Schon EA, Bonilla E, DiMauro S (1997) Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr 29: 131–149
Johns DR (1995) Mitochondrial DNA and disease. N Engl J Med 333: 638–644
Wallace DC (1999) Mitochondrial diseases in mouse and man. Science 283: 1482–1488
Bohan A, Droogan O, Nolan N, Mayne P, Bonham J, Thornton P, Farrell MA, Hegarty JE (2000) Mitochondrial DNA abnormalities without significant deficiency of intramitochondrial fatty acid beta oxidation enzymes in a well defined subgroup of patients with nonalcoholic steatohepatitis (abstract). Hepatology 32: 387A
Carrozzo R, Hirano M, Fromenty B, Casali C, Santorelli FM, Bonilla E, DiMauro S, Schon EA, Miranda AF (1998) Multiple mtDNA deletions features in autosomal dominant and recessive diseases suggest distinct pathogeneses. Neurology 50: 99–106
Hinokio Y, Suzuki S, Komatu K, Ohtomo M, Onoda M, Matsumoto M, Hirai S, Sato Y, Akai H, Ae K, Miyabayasi S, Abe R, Toyota T (1995) A new mitochondrial DNA deletion associated with diabetic amyotrophy, diabetic myoatrophy, and diabetic fatty liver. Muscle Nerve 3: S142–149
Feliciani C, Amerio P (1999) Madelung’s disease: inherited from an ancient Mediterranean population? N Engl J Medicine 340: 1481
Vila MR, Gamez J, Solano A, Playan A, Schwartz S, Santorelli FM, Cervera C, Casali C, Montoya J, Villarroya F (2000) Uncoupling protein-1 m RNA expression in lipomas from patients bearing pathogenic mitochondrial DNA mutations. Biochem Biophys Res Commun 278: 800–802
Guillausseau PJ, Massin P, Dubois-LaForgue D, Timsit J, Virally M, Gin H, Bertin E, Blickle JF, Bouhanick B, Cahen J, Caillat-Zucman S, Charpentier G, Chedin P, Derrien C, Ducluzeau PH, Grimaldi A, Guerci B, Kaloustian E, Murat A, Olivier F, Paques M, Paquis-Flucklinger V, Porokhov B, Samuel-Lajeunesse J, Vialettes B (2001) Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med 134: 721–728
Kadowaki H, Tobe K, Mori Y, Sakura H, Sakuta R, Nonaka I, Hagura R, Yazaki Y, Akanuma Y, Kadowaki T (1993) Lancet 341: 893–894
Minana JB, Gomez-Cambronero L, Lloret A, Pallardo FV, Del Olmo J, Escudero A, Rodrigo JM, Pelliin A, Vina JR, Vina J, Sastre J (2002) Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology 35: 1205–1214
Feldman G, Haouzi D, Moreau A, Durang-Schneider A-M, Bringuier A, Berson A, Mansouri A, Fau D, Pessayre D (2000) Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in FAS-mediated hepatic apoptosis in mice. Hepatology 31: 674–683
Feldsteine A, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD (2003) Hepatocyte apoptosis in patients with non-alcoholic steatohepatitis. Quantification and clinical relevance. Gastroenterology 124: 703A
Rashid A, Wu T-C, Huang CC, Chen CH, Lin HZ, Yang SQ, Lee FY, Diehl AM (1999) Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 29: 1131–1138
Powell EE, Searle J, Mortimer R (1989) Steatohepatitis associated with limb lipodystrophy. Gastroenterology 97: 1022–1024
Degoul F, Sutton A, Mansouri A, Cepanec C, Degott C, Fromenty B, Beaugrand M, Valla D, Pessayre D (1995) Homozygosity for alanine in the mitochondrial targeting sequence of manganese superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 108: 193–200
Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300: 1140–1142
Borkman M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV (1993) The relationship between insulin sensitivity and the fatty-acid composition of skeletal muscle phospholipids. N Engl J Med 328: 238–244
Sreekumar R, Rosado B, Rasmussen D, Charlton M (2003) Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38: 244–251
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221–1231
Tokar JL, Berg CL (2002) Therapeutic options in nonalcoholic fatty liver disease. Curr Treat Opt Gastroenterol 5: 425–436
Agrawal S, Bonkovsky HL (2002) Management of nonalcoholic steatohepatitis. J Clin Gastroenterol 35: 253–261
Younossi ZM, Diehl AM, Ong J (2002) Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 35: 746–752
McCullough AJ (2002) Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 34: 255–262
Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR (2003) Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women. JAMA 287: 2559–2562
Dixon JB, Bathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91–100
Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA (1999) Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 19: 263–264
Brodkin CA, Daniell W, Checkoway H, Echeverria D, Johnson J, Wang K, Sohaey R, Green D, Redlich C, Gretch D, Rosenstock L (1995) Hepatic ultrasonic changes in workers exposed to perchloroethylene. Occup Environ Med 52: 679–685
Redlich CA, Cullen MR (1997) Nonalcoholic steatohepatitis (letter). Ann Intern Med 127: 410
Saksena S, Johnson J, Ouiff SP, Elias E (1999) Diet and exercise: important first steps in therapy of NASH (abstract). Hepatology 30: 436
Bertram SR, Venter I, Stewart RI (1990) Weight loss in obese women—exercise versus dietary education. S Afr Med J 78: 15–18
Eriksson S, Eriksson KF, Bondesson L (1986) Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 220: 83–88
Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K (1997) Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27: 103–107
Keeffe EB, Adesman PW, Stenzel P, Palmer RM (1987) Steatosis and cirrhosis in an obese diabetic resolution of fatty liver by fasting. Dig Dis Sci 32: 441–445
Palmer M, Schaffner F (1990) Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99: 1408–1412
Rozental P, Biava C, Spencer H, Zimmerman HJ (1967) Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 12: 198–208
Drenick EJ, Simmons F, Murphy J (1970) Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 282: 829–834
Andersen T, Gluud C, Franzmann M-B, Christoffersen P (1991) Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12: 224–229
Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, de Vincenzo A (1994) Persistent hypertransaminasemia resolving after weight reduction in obese children. J Pediatr 125: 239–241
Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N (2000) Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 136: 739–743
Park HS, Kim MW, Shin ES (1995) Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 10414–10421
Eriksson J, Tuominen J, Valle T, Sundberg S, Sovijarvi A, Lindholm H, Tuomilehto J, Koivisto V (1998) Aerobic endurance exercise or circuit-type resistance training for individuals with impaired glucose tolerance? Horm Metab Res 30: 37–41
Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A (1997) Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 42: 1428–1432
Okita M, Hayashi M, Sasagawa T, Takagi K, Suzuki K, Kinoyama S, Ito T, Yamada G (2001) Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 17: 542–547
Capron JP, Delamarre J, Dupas JL, Braillon A, Degott C, Quenum C (1982) Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sci 54: 374–377
Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE (2003) Benefit of sustained weight loss and exercise in overweight patients with liver disease (abstract). Hepatology 34: 504A
van Baak MA (1999) Exercise training and substrate utilization in obesity. Int J Obes 23(Suppl 3): S11–S17
Hoppeler H (1999) Skeletal muscle substrate metabolism. Int J Obes 23(Suppl 3): S7–S10
Eden KB, Orleans T, Mulrow CD, Pender NJ, Teutsch SM (2002) Does counseling by clinicians improve physical activity? A summary of the evidence for the US preventive services task force. Ann Intern Med 137: 208–215
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350
Epstein FH (2000) Exercise limitations in health and disease. N Engl J Med 343: 632–640
Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA (2002) Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 347: 1483–1492
Jackicic JM, Winters C, Lang W, Wing RR (1999) Effects of intermittent exercise and use of home exercise equipment adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA 282: 1554–1560
Sothern MS, Loftin JM, Udall JN, Suskind RM, Ewing TL, Tang SC, Blecker U (2000) Safety, feasibility, and efficacy of a resistance training program in preadolescent obese children. Am J Med 319: 370–375
Schipper MEI, van Soest H, van Hattum J (2002) Improvement of steatosis after extracorporeal whole body hyperthermia in patients with chronic hepatitis C virus infection. Single Topic Conference on NASH Syllabus, Atlanta, Georgia, 2002
Dulloo AG (2002) Biomedicine. A sympathetic defense against obesity. Science 297: 780–781
Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BB (2002) betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297: 843–845
Cheuvront SN (2000) The Zone diet and athletic performance. Sports Med 27: 213–228
Landers P, Wolfe MM, Glore S, Guild R, Phillips L (2002) Effect of weight loss plans on body composition and diet duration. J Oklah State Med Assoc 95: 329–331
Amir R, Solga SF, Clark JM, Torbenson M, Cohen A, Diehl AM, Magnuson TH (2003) Dietary composition and fatty liver disease. Hepatology 34: 513A
Anonymous. (1998) Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158: 1855–1867
Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL (2000) AHA dietary guidelines: revision 2000. A statement for healthcare professionals from the nutrition committee of the American Heart Association. Stroke 31: 2751–2766
Clark MJ, Sterrett JJ, Carson DS (2000) Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 22: 899–910
Spieth LE, Harnish JD, Lenders CM, Raezer LB, Pereira MA, Hangen SJ, Ludwig DS (2000) A low glycemic index diet in the treatment of pediatric obesity. Arch Pediatr Adolesc Med 154: 947–951
Vessby B (2000) Dietary fat and insulin action in humans. Br J Nutr 83(Suppl 1): S91–S96
Kurihara T, Adachi Y, Yamagata M, Abe K, Akimoto M, Hashimoto H, Ishiguro H, Niimi A, Maeda A, Shigemoto M, et al (1994) Role of eicosapentanoic acid in lipid metabolism in the liver with special reference to experimental fatty liver. Clin Ther 16: 830–837
Nanji AA, Sadrzadeh SMH, Yang EK, Fogt F, Meydani M, Dannenberg AJ (1995) Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. Gastroenterology 109: 547–554
Lokesh B, LiCari J, Kinsella JE (1992) Effect of different dietary triglycerides on liver fatty acids and prostaglandin synthesis by mouse peritoneal cells. J Parenter Enteral Nutr 16: 316–321
Lanza-Jacoby S, Smythe C, Phetteplace H, Tabares A (1992) Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver. J Parenter Enteral Nutr 16: 353–358
Grattagliano I, Palmieri VO, Palasciano G (2002) Hepatotoxicity of polyunsaturated fatty acids in alcohol abuser. J Hepatol 37: 291–292
Luo J, Rizkalla SW, Boillot J, Alamowitch C, Chaib H, Bruzzo F, Desplanque N, Dalix AM, Durand G, Slama G (1996) Dietary (n-3) polyunsaturated fatty acids improve adipocyte insulin action and glucose metabolism in insulin-resistant rats: relation to membrane fatty acids. J Nutr 126: 1951–1958
Clarke SD, Baillie R, Jump DB, Nakamura MT (1997) Fatty acid regulation of gene expression. Its role in fuel partitioning and insulin resistance. Ann N Y Acad Sci 927: 178–187
Montagne O, Vedel I, Durand-Zalaski I (1999) Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economics evaluations. Clin Ther 21: 2027–2035
Daubioul C, Rousseau N, Demeure R, Gallez B, Taper H, Declerck B, Delzenne N (2002) Dietary fructans, but not cellulose, decrease triglyceride accumulation in the liver of obese Zucker fa/fa rats. J Nutr 132: 967–973
Kolanowski J (1999) A risk-benefit assessment of anti-obesity drugs. Drug Safety 20: 119–131
Favreaux JT, Ryu ML, Braunstein G, Orshansky G, Park SS, Coody GL, Love LA, Fong T-L (2002) Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 136: 590–595
Harrison SA, Fincke C, Helinski D, Torgerson S (2002) Orlistat treatment in obese, non-alcoholic steatohepatitis patients: a pilot study (abstract). Hepatology 36: 406
Yanovsky SZ, Yanovsky JA (2002) Obesity. N Engl J Med 346: 591–602
Mun EC, Blackburn GL, Matthews JB (2001) Current status of medical and surgical therapy for obesity. Gastroenterology 120: 669–681
Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ (1998) Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22: 222–226
Silverman EM, Sapala JA, Appelman HD (1995) Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 104: 23–31
Ranlov I, Hardt F (1990) Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 47: 208–214
Busetto L, Tregnaghi A, De Marchi F, Segato G, Foletto M, Sergi G, Favretti F, Lise M, Enzi G (2002) Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res 10: 408–411
Duchini A, Brunson ME (2001) Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 72: 156–171
Ackerman NB (1979) Protein supplementation in the management of degenerating liver function after jejunoileal bypass. Surg Gynecol Obstet 149: 8–14
Drenick EJ, Fisler J, Johnson D (1982) Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 82: 535–548
Laurin J, Lindor KD, Crippen JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB (1996) Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23: 1464–1467
Guma G, Viola L, Thome M, Galdame O, Albarez E (1997) Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial (abstract). Hepatology 26: 387
Ceriani R, Brunati S, Morini L, Sacchi E, Colombo G (1998) Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis (abstract). Hepatology 28: 386
Mendez-Sanchez N, Gonzalez V, Pichardo-Bahena R, Uribe M (2002) Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial (abstract). Hepatology 36: 412
Okan A, Astarcioglu H, Tankurt E, Sagul O, Altekin E, Astarcioglu I, Gonen O (2002) Effect of ursodeoxycholic acid on hepatic steatosis in rats. Dig Dis Sci 47: 2389–2397
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB (1996) Ursodeoxcholic acid or clofibrate in the treatment of non-alcoholic steatohepatitis: A pilot study. Hepatology 23: 1464–1467
Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39(3): 770–778
Kerai MD, Waterfield CJ, Kenyon SH, Asker DS, Timbrell JA (2001) The effect of taurine depletion by b-alanine treatment on the susceptibility to ethanol-induced hepatic dysfunction in rats. Alcohol Alcohol 36: 29–38
Kerai MD, Waterfield CJ, Kenyon SH, Asker DS, Timbrell JA (1999) Reversal of ethanolinduced hepatic steatosis and lipid peroxidation by taurine: a study in rats. Alcohol Alcohol 34: 529–541
Zaman N, Tam YK, Jewell LD, Coutts RT (1996) Effects of taurine supplementation in parenteral nutrition-associated hepatosteatosis and lidocaine metabolism. A study using isolated rat liver perfusion. Drug Metab Dispos Biol Fate Chem 24: 534–541
Kerai MD, Waterfield CJ, Kenyon SH, Asker DS, Timbrell JA (1998) Taurine: protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats. Amino Acids 15: 53–76
Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H (1996) Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 403: 607–613
Simon JB, Scheig R, Klatskin G (1968) Protection by orotic acid against the renal necrosis and fatty liver of choline deficiency. Proc Soc Exp Biol Med 129: 874–877
Buchman AL, Dubin M, Jenden D, Moukarzel A, Roch MH, Rice K, Gornbein J, Ament ME, Eckhert CD (1992) Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 102: 1363–1370
Demetriou AA (1992) Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. J Parenter Enteral Nutr 16: 487–488
Antisiewicz J, Nishizawa Y, Liu X, Usukura J, Wakabayashi T (1994) Suppression of the hydrazine-induced formation of megamitochondria in the rat liver by α-tocopherol. Exp Mol Pathol 60: 173–187
Soltys K, Dikdan G, Koneru B (2001) Oxidative stress in fatty liver of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 34: 13–18
Lavine JE (2000) Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136: 711–713
Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583–1592
Fu CS, Esrason K, Alshak NS, Conteas CN, Simmons VJ (1998) Dietary lecithin, antioxidant and vitamin B complex (LAB) decrease hepatic steatosis in patients with NASH (abstract). Gastroenterology 114: 1243
Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A (2001) Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15: 1667–1672
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with NASH. Am J Gastroenterol 98: 2485–2490
Alvaro D, Gigliozzi A, Piat C, Carli L, Bini A, La Rosa T, Furfaro S, Capocaccia L (1995) Effect of S-adenosyl-L-methionine on ethanol cholestasis and hepatotoxicity in isolated perfused rat liver. Dig Dis Sci 40: 1592–1600
Lu S (1998) Methionine adenosyltransferase and liver disease: it’s all about SAM. Gastroenterology 114: 403–407
Colell A, Garcia-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rodes J, Kaplowitz N, Fernandez-Checa JC (1997) Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-methionine. Hepatology 26: 699–708
Lieber CS (2002) S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol 27: 173–177
Nakano H, Yamaguchi M, Kaneshiro Y, Yoshida K, Kigawa G, Nagasaki H, Fujiwara Y, Matsumoto F, Kitamura N, Sasaki J, Kuzume M, Takeuchi S, Kumada K (1998) SAdenosyl-L-methionine attenuates ischemia-reperfusion injury of steatotic rats. Transplant Proc 30: 3735–3736
Avila MA, Carretero MV, Rodriguez EN, Mato JM (1998) Regulation by hypoxia of methionine adenosyltransferase activity and gene expression in rat hepatocytes. Gastroenterology 114: 364–371
Mazzanti R, Arcangeli A, Salvadori G, Smorlesi C, Di Perri T, Auteri A, Boggiano CA, Pippi L, Toti M, Boncompagni P, Angioli D, Caremani M, Magnolfi F, Camarri E, Motta R, Forconi A, Tommasi AC, Lomi M, Soldi A (1978) The anti-steatotic effect of sulfo-adenosylmethionine (SAMe) in various forms of chronic hepatopathy. Multicentric research. Minerva Med 69: 3283–3292
Labo G, Gasbarrini GB (1975) Therapeutic action of S-adenosylmethionine in some chronic hepatopathies. Minerva Med 66: 1563–1570
Labo G, Gasbarrini G, Miglio F (1972) Various effects of SAM dependent transmethylations in hepatology. Minerva Med 63: 2007–2017
Neuschwander-Tetri BA (2001) Betaine: an old therapy for a new scourge. Am J Gastroenterol 96: 2534–2546
Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD (2001) Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96: 2711–2717
Miglio F, Rovati LC, Santoro A, Setnikar I (2000) Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 50: 722–727
Nakano H, Nagasaki H, Yoshida K, Kigawa G, Fujiwara Y, Kitamura N, Kuzume M, Takeuchi S, Sasaki J, Shimura H, Yamaguchi M, Kumada K (1998) N-Acetylcysteine and anti-ICAM-1 monoclonal antibody reduce ischemia-reperfusion injury of the steatotic rat liver. Transplant Proc 30: 3763
Nakano H, Nagasaki H, Barama A, Boudjema K, Jaeck D, Kumada K, Tatsuno M, Baek Y, Kitamura N, Suzuki T, Yamaguchi M (1997) The effect of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet. Hepatology 26: 670–678
Gulbahar O, Karasu ZA, Ersoz G, Akarca US, Musoglu A (2000) Treatment of nonalcoholic steatohepatitis with N-acetylcysteine (abstract). Gastroenterology 118: 1444
Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC (2000) Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos Biol Fate Chem 28: 1270–1273
Azuma Y, Shinohara M, Wang PL, Hidaka A, Ohura K (2001) Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNF-α and IL-12 by macrophages via H2-receptors. Int J Immunopharmacol 1: 1867–1875
Villa RF, Gorini A (1997) Pharmacology of lazaroids and brain energy metabolism: a review. Pharmacol Rev 49: 99–136
Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, DeSimone C, Song X, Diehl AM (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37: 343–350
DeFronzo RA (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131: 281–303
Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96: 519–525
Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, Tajima N (2001) Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy—a randomized controlled trial. Metabolism 50: 414–417
Acosta RC, Molina EG, O’Brien CB, Cobo MC, Amaro R, Neff GW, Schiff ER (2001) The use of pioglitazone in nonalcoholic steatohepatitis (abstract). Gastroenterology 120: 546
Neuschwander-Tetri BA, Brunt EM, Bacon BR, Sponseller C, Wehmeier KR, Hampton K (2002) Histologic improvement in NASH following increased insulin sensitivity with the PPAR-γ ligand rosiglitazone for 48 weeks (abstract). Hepatology 36: 379
Galli A, Crabb DW, Ceni E, Salzano R, Melo T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924–1940
Azuma T, Tomita K, Kato S, Adachi M, Inokuchi N, Kitamura N, Nishimura T, Ishii H (2002) A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis (abstract). Hepatology 36: 406
Sanyal AJ, Contos MJ, Sargeant C, Stravitz RT, Luketic VA, Sterling RK, Shiffman ML (2002) A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis (abstract). Hepatology 36: 382
Vamecq J, Latruffe N (1999) Medical significance of peroxisome proliferator-activated receptors. Lancet 354: 141–148
Ribon V, Johnson JH, Camp HS, Saltiel AR (1998) Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci U S A 95: 14751–1476
Kelly IE, Han TS, Walsh K, Lean ME (1999) Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22: 288–293
Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE (1997) Effects of troglitazone and metformin on glucose and lipid metabolism. Biochem Pharmacol 54: 801–808
Aubert J, Champigny O, Saint-Marc P, Negrel R, Collins S, Ricquier D, Ailhaud G (1997) Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 238: 606–611
Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitmen ML, Taylor SI (2000) Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133: 263–274
Sanyal AJ, Contos MJ, Sargeant C, Stravitz RT, Luketic VA, Sterling RK, Shiffman ML (2002) A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis. Hepatology 36: 382
Neuschwander-Tetri BA, Brunt EM, Wehmier KR, Sponseller CA, Hampton K, Bacon BR (2003) Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis (2003) Hepatology 38(4): 434–440
Lutchman GA, Promrat K, Soza A, Heller T, Mi L, Ghany M, Park Y, Freedman R, Yanovsky J, Kleiner D, Liang TJ, Hoofnagle J (2003) Biochemical relapse and continued weight gain in subjects with NASH after discontinuation of pioglitazone. Hepatology 34: 510A
Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese leptin-deficient mice. Nat Med 6: 998–1003
Coyle WJ, Delaney N, Yoshihashi A, Lawson P (1999) Metformin treatment in patients with nonalcoholic steatohepatitis (abstract). Gastroenterology 116: 1198
Urso R, Visco-Comandini U (2002) Metformin in non-alcoholic steatohepatitis. Lancet 359: 355–356
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358: 893–894
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167–1174
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359: 2072–2077
Santomauro ATMG, Boden G, Sliva MER, Rocha DM, Santos RF, Ursich MJM, Strassmann PG, Wajchenberg BL (1999) Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48: 1836–1841
Nestler JE, Jakubowicz DJ, Iuorno MJ (2000) Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol 13(Suppl 5): 1295–1298
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ladwig J, Rakela J, McGill DB (1996) Ursodeoxcholic acid or clofibrate in the treatment of non-alcoholic steatohepatitis: A pilot study. Hepatology 23: 1464–1467
Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H (1999) Bezafibrate for tamoxipheninduced non-alcoholic steatohepatitis. Lancet 353: 1802
Basaranoglu M, Acbay O, Sonsuz A (1999) A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31: 384
Caldwell SH, Zaidman JS, Hespenheide EE (2003) The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit (editorial). Pharmacoepidemiology Drug Safety 12(4): 303–306
Horlander JC, Kwo PY, Cummings OW, Koukoulis G (2001) Atorvastatin for the treatment of NASH (abstract). Gastroenterology 120: 544
Nair S, Wiseman M (2002) HMG-CoA reductase inhibitors in nonalcoholic fatty liver disease: is their potential hepatotoxicity an issue in these patients? A case control study based on histology (abstract). Hepatology 36: 409
Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137: 581–585
Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F (2001) Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J Hepatol 35: 816–822
Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS (2002) Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35: 898–904
Facchini FS, Hua NW, Stoohs RA (2002) Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122: 931–939
Pawlotsky J-M (2003) Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7: 45–66
Adinolfi LE, Utili R, Andreana A, Tripodi M-F, Marracino M, Gambardella M, Giordano M, Ruggiero G (2001) Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 46: 1677–1683
Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL (2002) Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. J Hepatol 36: 729–736
Mihm S, Fayyazi A, Hartmann H, Ramadori G (1997) Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25: 735–739
Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, Negro F (2001) Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 39: 119–124
Adinolfi LE, Gambardella M, Andreana A, Tripodi M-F, Utili R, Ruggiero G (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358–1364
Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski J-P, Borisch B, Hadengue A, Negro F (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33: 106–115
Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F (2001) Expression of liver steatosis in hepatitis C virus infection and pattern of response to α-interferon. J Hepatol 35: 307
Mendler MH, Panesar J, Govindarajan S, Milstein S, Lindsay K (2002) Changes in fatty infiltration of the liver in patients treated for chronic hepatitis C: a viral or host effect (abstract)? Hepatology 36: 404
Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE (2002) Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 53(3): 413–419
Nair S, Verma S, Thuluvath PJ (2002) Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 35: 105–109
Czaja AJ (1997) Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg 3: 185–186
Molloy RM, Komorowski R, Varma RR (1997) Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 3: 177–178
Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM (1997) Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 3: 174–176
Kim WR, Poterucha JJ, Porayko MK, Dickerson ER, Steers JL, Weisner RH (1996) Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 62: 1802–1805
Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ (2001) Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transplantation 7: 363–373
Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparis N (2001) Cryptogenic cirrhosis and post-transplantation non-alcoholic fatty liver disease. Liver Transplantation 7: 797–801
Cassarino DS, Swerdlow RH, Parks JK, Parker WD, Bennett JP (1998) Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer’s disease cybrids. Biochem Biophys Res Commun 248: 168–173
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Tokyo
About this paper
Cite this paper
Caldwell, S.H. et al. (2005). Nonalcoholic Fatty Liver (NAFL): Overview. In: Okita, K. (eds) NASH and Nutritional Therapy. Springer, Tokyo. https://doi.org/10.1007/4-431-27172-4_1
Download citation
DOI: https://doi.org/10.1007/4-431-27172-4_1
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-21388-8
Online ISBN: 978-4-431-27172-7
eBook Packages: MedicineMedicine (R0)